MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2024.2391445

Медицинская библиотека · The Journal of dermatological treatment · 2024

A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib.

Huang Xin, Zhang Guiying, Luo Shuaihantian

Клинический случайСтатьяПеревод в очереди

Аннотация

Purpose: Amyopathic dermatomyositis (ADM) is a rare, idiopathic, connective tissue disease and melanoma differentiation-associated protein 5 (MDA5) antibody-positive ADM is more treatment-resistant, especially in patients with interstitial lung disease (ILD). The purpose of this article is to report a case of anti-MDA5-positive ADM successfully treated with JAK inhibitor Upadacitinib. Materials and methods: A 35-year-old Chinese woman presented with recurrent itchy erythema on her face and scalp for 4 years. Upon examination, there were heliotrope erythema and eyelid edema, reddish rash on neck and scalp. Biopsy of the lesions was consistent with DM and a line blot assay confirmed the presence of anti-MDA5 antibodies. This patient was treated with oral Upadacitinib at a dosage of 30 mg daily.

Results

After 6 weeks of treatment, she achieved complete clinical remission with no reported side effects or instances of relapse. The antibody titer of anti-MDA5 was also decreased.

Conclusions

Upadacitinib may be a potential drug candidate in patients with treatment-resistant ADM, especially in cases with refractory cutaneous conditions.

Для цитирования: Huang Xin, Zhang Guiying, Luo Shuaihantian. A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib.. The Journal of dermatological treatment. 2024. DOI: 10.1080/09546634.2024.2391445.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.